Immune cell therapy for B-cell lymphoma and leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This clinical trial tests a new cell therapy, CT1194D, for people whose B-cell lymphoma (a type of blood cancer) or B-cell acute lymphoblastic leukemia has come back or is not responding to standard treatments. The goal is to see if this therapy can help shrink tumors or improve blood cell counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a diagnosed B-cell lymphoma (like diffuse large B-cell lymphoma, mantle cell lymphoma, or follicular lymphoma) or B-cell acute lymphoblastic leukemia that has returned or not responded to previous treatments.
- Your cancer cells must have a specific marker called CD19 and/or CD20 on their surface (a standard test can check this).
- You need to have measurable disease (a tumor that can be seen on a CT scan or PET scan).
- You must have good performance status (able to do most daily activities), with an ECOG score of 0-2 depending on the group.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an investigational cell therapy called CT1195E for people with certain types of B-cell lymphoma or acute lymphoblastic leukemia that has come back or stopped responding to treatment. The goal is to see if CT1195E can help control the cancer.
This study tests a new therapy called CT1194C for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. It aims to see if the therapy is safe and effective.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
Hear when a new Relapsed/Refractory B-Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.